Disrupted sleep in breast and prostate cancer patients undergoing radiation therapy: The role of coping processes

Department of Psychology, Pitzer College, Claremont, CA 91711, USA.
Psycho-Oncology (Impact Factor: 2.44). 07/2009; 19(7):767-76. DOI: 10.1002/pon.1639
Source: PubMed


Sleep problems are a common complaint in cancer patients that have been understudied.
This study examined changes in sleep in 33 breast cancer (BC) patients and 23 prostate cancer (PC) patients during radiation therapy and over a 6-month followup. Coping processes were examined as predictors of sleep. Self-reported sleep was assessed at eight time-points before, during, and after treatment using the Medical Outcomes Study-Sleep Scale. The COPE Scale was used to assess coping processes before treatment onset.
Mixed effects linear modeling analyses revealed that both BC and PC patients reported the most sleep problems prior to and during the early weeks of treatment. Coping strategies predicted sleep trajectories in both groups. In particular, approach coping predicted better sleep in PC patients, whereas avoidance coping predicted worst sleep in both PC and BC patients (p's<0.05).
These findings highlight the importance of evaluating sleep in patients as they undergo treatment for cancer. Additionally, they suggest that interventions aimed at increasing the use of approach-oriented coping strategies may improve sleep and quality of life in these patients.

Download full-text


Available from: Michael A Hoyt, May 13, 2014
    • "Medical Outcomes Study Sleep Scale (MOS-SS; Hays et al., 2005): The MOS-SS is a validated scale comprising 12 items, including questions about sleep disturbance, sleep adequacy, daytime somnolence, snoring, waking up short of breath or with a headache, and sleep quantity. MOS-SS has been used as an instrument to investigate disrupted sleep in cancer populations (Bower et al., 2000; Thomas et al., 2010). It is validated for a 1-week recall, which is what we used in the present study and a previous study (Nakamura et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer survivors experience high levels of distress, associated with a host of negative psychological states, including anxiety, depression, and fear of recurrence, which often lead to sleep problems and reduction in quality of life (QOL) and well-being. As a neuropeptide hormone associated with affiliation, calmness, and well-being, oxytocin may be a useful biological measure of changes in health outcomes in cancer survivors. In this exploratory study, which comprised a subset of participants from a larger study, we evaluated (a) the feasibility and reliability of salivary oxytocin (sOT) levels in cancer survivors and (b) the effects of 2 sleep-focused mind-body interventions, mind-body bridging (MBB) and mindfulness meditation (MM), compared with a sleep hygiene education (SHE) control, on changes in sOT levels in 30 cancer survivors with self-reported sleep disturbance. Interventions were conducted in 3 sessions, once per week for 3 weeks. Saliva samples were collected at baseline, postintervention (~1 week after the last session), and at the 2-month follow-up. In this cancer survivor group, we found that intra-individual sOT levels were fairly stable across the 3 time points, of about 3 months' duration, and mean baseline sOT levels did not differ between females and males and were not correlated with age. Correlations between baseline sOT and self-report measures were weak; however, several of these relationships were in the predicted direction, in which sOT levels were negatively associated with sleep problems and depression and positively associated with cancer-related QOL and well-being. Regarding intervention effects on sOT, baseline-subtracted sOT levels were significantly larger at postintervention in the MBB group as compared with those in SHE. In this sample of cancer survivors assessed for sOT, at postintervention, greater reductions in sleep problems were noted for MBB and MM compared with that of SHE, and increases in mindfulness and self-compassion were observed in the MBB group compared with those in SHE. The findings in this exploratory study suggest that sOT may be a reliable biological measure over time that may provide insight into the effects of mind-body interventions on health outcomes in cancer survivors. © The Author(s) 2015.
    No preview · Article · Apr 2015 · Integrative Cancer Therapies
  • Source
    • "These studies show that throughout the cancer treatment process sleep problem rates are elevated and remain relatively stable.7,22 Other studies have found that the prevalence of sleep problems declines only slightly over time, following completion of anticancer treatment.5,23–25 These prospective studies demonstrate that sleep problem rates remain elevated for years in cancer patients (those who are still undergoing cancer treatments) and continue to be a chronic condition that survivors (those patients who are finished with their cancer treatments) experience. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep problems are highly prevalent in cancer patients undergoing chemotherapy. This article reviews existing evidence on etiology, associated symptoms, and management of sleep problems associated with chemotherapy treatment during cancer. It also discusses limitations and methodological issues of current research. The existing literature suggests that subjectively and objectively measured sleep problems are the highest during the chemotherapy phase of cancer treatments. A possibly involved mechanism reviewed here includes the rise in the circulating proinflammatory cytokines and the associated disruption in circadian rhythm in the develop-ment and maintenance of sleep dysregulation in cancer patients during chemotherapy. Various approaches to the management of sleep problems during chemotherapy are discussed with behavioral intervention showing promise. Exercise, including yoga, also appear to be effective and safe at least for subclinical levels of sleep problems in cancer patients. Numerous chal-lenges are associated with conducting research on sleep in cancer patients during chemotherapy treatments and they are discussed in this review. Dedicated intervention trials, methodologi-cally sound and sufficiently powered, are needed to test current and novel treatments of sleep problems in cancer patients receiving chemotherapy. Optimal management of sleep problems in patients with cancer receiving treatment may improve not only the well-being of patients, but also their prognosis given the emerging experimental and clinical evidence suggesting that sleep disruption might adversely impact treatment and recovery from cancer.
    Full-text · Article · Dec 2012 · Nature and Science of Sleep
  • Source
    • "In a prospective study of neoadjuvant androgen deprivation therapy prior to radiotherapy, prostate cancer patients reported sleeping less well following androgen deprivation therapy (Stephens et al. 2007). Similarly, another prospective study found that sleep problems were most severe before radiotherapy and gradually declined over 6 months (Thomas et al. 2010). Half of the men in this study were taking androgen deprivation therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HANISCH L.J., GOONERATNE N.S., SOIN K., GEHRMAN P.R., VAUGHN D.J. & COYNE J.C. (2010) European Journal of Cancer Care Sleep and daily functioning during androgen deprivation therapy for prostate cancer A limited body of evidence suggests that sleep problems are common in prostate cancer patients undergoing androgen deprivation therapy, yet little is known about sleep characteristics and the effects of poor sleep on daily functioning in this population. This study assessed sleep in 60 prostate cancer patients taking androgen deprivation therapy with wrist actigraphy and daily diaries for 7 days. The Epworth Sleepiness Scale and the general version of the Functional Assessment of Cancer Therapy scale were also administered. On average, total sleep time was 5.9 (SD = 1.4) h, and sleep efficiency was 75% (SD = 12.0) as assessed by actigraphy. There was generally poor concordance between actigraphy and daily diary for most sleep metrics. Subjects reported awakening, on average, 2.7 times per night, most commonly for nocturia and hot flashes. Assessment of daily functioning showed that participants had mild daytime sleepiness, which was predicted by total sleep time (F(1,47) = 4.5, P= 0.04) General quality of life was not impaired. This study supports more research on the predictors of poor sleep in order to identify effective interventions.
    Full-text · Article · Jul 2011 · European Journal of Cancer Care
Show more